Screener
Neurocrine Biosciences NBIX Q2 2026 earnings
Reported July 30, 2026 · After market close
Revenue$959.0MBeat by $67.8M
EPS$1.39Miss by $0.26
Revenue estimate$891.2M
EPS estimate$1.65
“As our commercial portfolio of first-in-class medicines continues to grow, so does our capacity to reinvest in innovation, advance a differentiated late-stage pipeline and pursue strategic opportunities that strengthen the company for the long term. With multiple important clinical milestones in 2027, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia, we are building an enduring company poised to deliver meaningful value for patients and shareholders for years to come.”
Next report
Oct 27, 2026 (in a month)Revenue estimate$1.0B
EPS estimate$2.59
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Neurocrine Biosciences report Q2 2026 earnings?
- Neurocrine Biosciences (NBIX) reported Q2 2026 earnings on July 30, 2026 after market close.
- What were Neurocrine Biosciences's Q2 2026 revenue and EPS?
- Neurocrine Biosciences reported revenue of $959.0M and eps of $1.39 for Q2 2026.
- Did Neurocrine Biosciences beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $891.2M by $67.8M. EPS missed the consensus estimate of $1.65 by $0.26.
- How did Neurocrine Biosciences's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 39.5% from $687.5M a year earlier and eps grew 31.1% from $1.06.
- Where can I find Neurocrine Biosciences's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0000914475-26-000035) and the 10-Q periodic report (0000914475-26-000037) directly on SEC EDGAR. The filing index links above go to sec.gov.
